Targeting glycolytic pathway with 2-Deoxy-glucose enhances lapatinib sensitivity in HER2-amplified breast cancer

被引：0
|
作者：
Chen, Xiaosong [1 ]
Liu, Junjun [1 ]
Ward, Toby [2 ]
Liu, Xiaofei [2 ]
Mao, Yan [1 ]
Bockhorn, Jessica [2 ]
Shen, Kunwei [1 ]
Pegram, Mark [2 ]
机构：
[1] Shanghai Jiao Tong Univ, Sch Med, Ruijin Hosp, Shanghai 200030, Peoples R China
[2] Stanford Canc Inst, Stanford, CA USA
来源：
CANCER RESEARCH | 2015年 / 75卷
关键词：
D O I：
10.1158/1538-7445.AM2015-713
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
713
引用
收藏
页数：2
相关论文
共 50 条
  • [41] Transcriptome and genome evolution during HER2-amplified breast neoplasia
    Peipei Lu
    Joseph Foley
    Chunfang Zhu
    Katherine McNamara
    Korsuk Sirinukunwattana
    Sujay Vennam
    Sushama Varma
    Hamid Fehri
    Arunima Srivastava
    Shirley Zhu
    Jens Rittscher
    Parag Mallick
    Christina Curtis
    Robert West
    Breast Cancer Research, 23
  • [42] The NEDD8 pathway as a therapeutic target in HER2-amplified colorectal cancer.
    Invrea, Federica
    Carugo, Alessandro
    Petti, Consalvo
    Draetta, Giulio
    Medico, Enzo
    CANCER RESEARCH, 2022, 82 (23)
  • [43] The role of HER2 and HER3 in HER2-amplified cancers beyond breast cancers
    Majumder, Avisek
    Sandhu, Manbir
    Banerji, Debarko
    Steri, Veronica
    Olshen, Adam
    Moasser, Mark M.
    SCIENTIFIC REPORTS, 2021, 11 (01) : 9091
  • [44] AKT3 activation mediates resistance to HER2-targeted therapies in HER2-amplified breast cancer
    Sanz, F. Carmona
    Montemurro, F.
    Rossi, V.
    Verma, C.
    Berger, M.
    Baselga, J.
    Scaltriti, M.
    EUROPEAN JOURNAL OF CANCER, 2014, 50 : 27 - 28
  • [45] Dacomitinib (PF-00299804), an Irreversible Pan-HER Inhibitor, Inhibits Proliferation of HER2-Amplified Breast Cancer Cell Lines Resistant to Trastuzumab and Lapatinib
    Kalous, Ondrej
    Conklin, Dylan
    Desai, Amrita J.
    O'Brien, Neil A.
    Ginther, Charles
    Anderson, Lee
    Cohen, David J.
    Britten, Carolyn D.
    Taylor, Ian
    Christensen, James G.
    Slamon, Dennis J.
    Finn, Richard S.
    MOLECULAR CANCER THERAPEUTICS, 2012, 11 (09) : 1978 - 1987
  • [46] Trastuzumab Plus Pertuzumab Resistance Does Not Preclude Response to Lapatinib Plus Trastuzumab in HER2-Amplified Colorectal Cancer
    Fakih, Marwan G.
    ONCOLOGIST, 2018, 23 (04): : 474 - 477
  • [47] Trastuzumab and Emerging Targeted Therapies for HER2-Amplified Early-Stage Breast Cancer
    Gajria, Devika
    ONCOLOGY-NEW YORK, 2009, 23 (11): : 28 - 35
  • [48] Chemical probing of HER2-amplified cancer cells identifies TORC2 as a particularly effective secondary target for combination with lapatinib
    Amin, Dhara N.
    Ruiz-Saenz, Ana
    Gulizia, Nathaniel
    Moasser, Mark M.
    ONCOTARGET, 2015, 6 (38) : 41123 - 41133
  • [49] Landscape of somatic allelic imbalances and copy number alterations in HER2-amplified breast cancer
    Johan Staaf
    Göran Jönsson
    Markus Ringnér
    Bo Baldetorp
    Åke Borg
    Breast Cancer Research, 13
  • [50] Monosomy 17 in potentially curable HER2-amplified breast cancer: prognostic and predictive impact
    Page, David B.
    Wen, Hannah
    Brogi, Edi
    Dure, Dana
    Ross, Dara
    Spinelli, Kateri J.
    Patil, Sujata
    Norton, Larry
    Hudis, Clifford
    McArthur, Heather L.
    BREAST CANCER RESEARCH AND TREATMENT, 2018, 167 (02) : 547 - 554
12345